EpicGenetics Moves into New Facility, Expanding Capacity by 4X

LOS ANGELES--(BUSINESS WIRE)-- EpicGenetics, the biomedical company that developed and offers the FM/a Test, the FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia, moved into a new facility that quadruples its capacity. The new facility is 50,000 square feet and located at 11801 West Olympic in Los Angeles. The move enables the company to expand its lab, support employee growth and facilitate new research initiatives.

“This gives us the space and bandwidth we need to deal with the spike in demand for the FM/a test,” said Dr. Bruce Gillis, CEO of EpicGenetics. “Fibromyalgia is finally being recognized as a legitimate disease, and our new facility positions us as the best-equipped lab for diagnosis and study of the disease.”

In August, the company announced an FDA approved clinical trial that will be held at Massachusetts General Hospital. The trial will evaluate the potential for BCG (an inexpensive generic vaccine used globally to prevent tuberculosis) to reverse fibromyalgia.

For more information about the test or the trial, visit www.fmtest.com.

About EpicGenetics

EpicGenetics, Inc. is a privately held biomedical company based in Los Angeles, California that developed and manufactures the FM/a^® Test. EpicGenetics is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers. More information is available at www.FMTest.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005127/en/